Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma

2011 ◽  
Vol 83 (9) ◽  
pp. 1582-1584 ◽  
Author(s):  
Motoki Ohta ◽  
Takashi Taga ◽  
Akitaka Nomura ◽  
Hirofumi Kato ◽  
Tomoyuki Takano ◽  
...  
Keyword(s):  
Varicella Zoster Virus ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Virus Encephalitis ◽  
Varicella Zoster ◽  
Barr Virus ◽  
Cytomegalovirus Reactivation ◽  
Epstein Barr

Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis

2016 ◽  
Vol 83 (4) ◽  
pp. 412-415 ◽  
Author(s):  
Cindy Mourgues ◽  
Cecile Henquell ◽  
Zuzana Tatar ◽  
Bruno Pereira ◽  
Cinthya Nourisson ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Varicella Zoster Virus ◽  
Epstein Barr Virus ◽  
Varicella Zoster ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients

1993 ◽  
Vol 4 (2) ◽  
pp. 84-88 ◽  
Author(s):  
Walter F Schlech ◽  
Nancy Meagher ◽  
Allan D Cohen ◽  
Philip Belitsky ◽  
AS MacDonald ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Varicella Zoster Virus ◽  
Epstein Barr Virus ◽  
Oral Acyclovir ◽  
Cmv Infection ◽  
Varicella Zoster ◽  
Barr Virus ◽  
Epstein Barr ◽  
Simplex Virus

Fifty renal transplant patients were randomized to receive either 800 mg acyclovir by mouth four times daily or identical placebo tablets for prophylaxis of herpes simplex infection. Patients were followed weekly to assess reactivation of herpes simplex, varicella zoster virus, Epstein-Barr virus or cytomegalovirus (CMV) infections. The patients received standard immunosuppressive regimens including cyclosporine A. Acyclovir suppressed secretion of herpes simplex virus in treated patients (P=0.001). Three episodes of mucocutaneous herpes simplex virus occurred in placebo recipients and one in a noncompliant acyclovir recipient. A clinically important difference in graft survival was demonstrated, but because of sample size failed to reach statistical significance (P=0.11). No reactivation of varicella zoster virus, Epstein-Barr virus or CMV infection was detected in either group. Toxicity was limited to central nervous irritability. The authors conclude that high dose oral acyclovir provides effective prophylaxis for prevention of herpes simplex virus infections in renal transplantation and may be associated with increased graft survival, perhaps from suppression of CMV infection.

Sign in / Sign up

Export Citation Format

Share Document